TG Therapeutics reports Q3 net loss of $35.8M; ublituximab PDUFA set for Dec 28, 2022

TG THERAPEUTICS, INC.

2022-Q3 EPS reported -$1.08 revenue$2,705,000

Net loss of $35.8M for Q3 2022 vs $85.6M in Q3 2021; nine-month net loss of $145.3M.
Cash, equivalents and securities totaled $197.7M as of Sept 30, 2022; funding expected into 2024.
R&D expense fell to $20.8M from $52.0M; SG&A decreased to $14.3M from $34.9M YoY.
Ublituximab BLA for relapsing MS has PDUFA goal date of December 28, 2022; commercial prep ongoing.
Company plans to launch ublituximab early 2023 if FDA approves.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TG THERAPEUTICS, INC. reported three months ended September 30, 2022 results: net income $35.8 million.

Period: three months ended September 30, 2022
Net income: $35.8 million
Result: reported results

Exact text from the filing

Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TG THERAPEUTICS, INC. reported nine months ended September 30, 2022 results: net income $145.3 million.

Period: nine months ended September 30, 2022
Net income: $145.3 million
Result: reported results

Exact text from the filing

Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-017292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.